REMS (Risk Evaluation and Mitigation Strategy)

A Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program that the U.S. Food and Drug Administration (FDA) can require a drug or biologic manufacturer to implement when a product’s serious risks would otherwise outweigh its benefits without additional controls beyond standard professional labeling. FDA’s authority to require a REMS comes from the Food and Drug Administration Amendments Act of 2007 (FDAAA), which added Section 505-1 to the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1), the same statute the Durham-Humphrey Amendment amended in 1951 to create the prescription-only drug class. A REMS can be required at the time of approval, or imposed on an already-marketed drug if FDA becomes aware of new safety information.

n

What a REMS Can Require

n

Not every REMS uses every tool available under the statute. FDA tailors the specific elements to the drug’s risk profile, and a REMS may include any combination of:

n

n
• Medication Guide or Patient Package Insert — FDA-approved, patient-directed information dispensed with the prescription, distinct from the professional prescribing label.

n

• Communication Plan — materials FDA requires the manufacturer to send to prescribers, pharmacists, or other healthcare providers to alert them to the serious risk and any REMS-specific requirements before they prescribe or dispense the drug.

n

• Elements to Assure Safe Use (ETASU) — the most restrictive tier, reserved for drugs with especially severe risks. ETASU can require prescriber certification/training, pharmacy certification, dispensing only in certain healthcare settings, mandatory patient monitoring or lab testing, or enrollment of patients in a registry.

n

• Implementation System — required whenever a REMS includes ETASU, this is the operational infrastructure (often a shared, cross-manufacturer platform for products in the same drug class) that monitors and enforces compliance with the ETASU requirements.

n

n

Manufacturers must also periodically assess and report to FDA on whether the REMS is achieving its stated goals, and FDA can require modifications if it is not.

n

Why REMS Exists: Balancing Access and Risk

n

REMS was created specifically as a middle path between two blunter tools: approving a drug with ordinary labeling alone, or refusing to approve it (or withdrawing it) because of unacceptable risk. By attaching enforceable risk-mitigation conditions to approval, FDA can authorize access to therapies with serious but manageable risks — opioid analgesics with abuse-deterrent programs, isotretinoin (associated historically with the iPLEDGE program) for severe teratogenic risk, or clozapine for a risk of severe neutropenia — that would be difficult to approve, or difficult to keep on the market, under standard labeling alone.

n

REMS vs. Standard Product Labeling

n

Every prescription drug has FDA-approved labeling (the package insert) describing risks, warnings, and contraindications. A REMS is not a substitute for labeling and does not replace it — it is an additional, legally enforceable layer of risk control that goes beyond what labeling alone can accomplish, because labeling relies on prescribers and patients reading and following it voluntarily, while REMS elements (particularly ETASU) can be structurally enforced through certification, restricted dispensing, or mandatory monitoring.

n

Relevance to Clinical Research Administration

n

REMS requirements are directly relevant to clinical trial operations when an investigational or already-approved REMS drug is used in a study: sites may need prescriber/pharmacy certification under the drug’s REMS program before they can dispense study drug, and research administrators coordinating Investigational New Drug (IND) applications or expanded access / compassionate use requests for a REMS-restricted product need to build REMS enrollment and certification into study startup timelines, since it is a separate compliance track from IRB approval or the IND itself.

n

Frequently Asked Questions

n

Is a REMS the same as a black box warning?

n

No. A boxed warning is part of the drug’s professional labeling, calling attention to a serious risk in the prescribing information itself. A REMS is a separate, additional program with its own enforceable requirements (which can include a Medication Guide, communication plan, or ETASU) layered on top of labeling. A drug can have a boxed warning without a REMS, and vice versa, though high-risk drugs often carry both.

n

Who has to comply with a REMS?

n

Depending on the specific REMS, obligations can fall on the manufacturer (implementing and reporting on the program), prescribers (completing required training or certification), pharmacies (verifying certification status before dispensing), and in some ETASU-level programs, patients themselves (enrolling in a registry or completing required monitoring).

n

How long does a REMS stay in place?

n

A REMS remains in effect until FDA determines it is no longer necessary — for example, because post-market data show the risk is adequately managed through routine labeling, or because the drug’s risk-benefit profile has otherwise changed. FDA periodically reviews REMS programs against their stated goals and can modify, or eliminate, elements it finds no longer justified.